Scripps Cancer Center's 39th Annual Conference: Clinical Hematology & Oncology 2019


 

Novel Treatment Options for High-Risk/Eldery AML Patients: CPX-351, Glasdegib + LDAC & Venetoclax + Hypomethylating Agents

149 views
July 19, 2019
0 Comments
Login to view comments. Click here to Login
Malignant Hematology